{
  "ticker": "AHI",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975610",
  "id": "02975610",
  "pages": 28,
  "price_sensitive": true,
  "date": "20250731",
  "time": "1814",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mdlskknrxtnc.pdf",
  "summary": "### **Material Information Summary (ASX: AHI \u2013 31 July 2025 Announcement)**  \n\n#### **Capital Raising & Funding**  \n- **Structure**: Blended private placement ($2.75M) + convertible note facility ($2.75M).  \n- **Total Capital**: Up to **AUD $5.5M** (Oakley Capital Partners).  \n- **Timetable**:  \n  - Shareholder approval sought at upcoming General Meeting (date not specified).  \n  - Settlement expected **before ASX reinstatement**.  \n- **Additional Funding**: Targeting **USD $6M** from strategic investors/current shareholders.  \n- **Non-Dilutive Capital**: Up to **AUD $3M** via R&D grants (FY2024\u201326; pending AusIndustry approval).  \n\n#### **Operational & Financial Highlights (Appendix 4C)**  \n- **Cash Balance**: **AUD $2k** (30 June 2025).  \n- **Monthly Cash Burn**: Reduced to **AUD $276k**.  \n- **Revenue**: Minimal (specifics not disclosed; focus on commercial partnerships).  \n- **Debt**:  \n  - **Bridging Loan (Quarters Academy)**: AUD $2.5M outstanding (extended repayment terms pending reinstatement).  \n  - **KOR Convertible Note (USD $4M)**: Delayed due to fund transfer issues; no funds received.  \n\n#### **ASX Reinstatement Progress**  \n- **Conditions**:  \n  - Lodge **FY2024 Annual Report by 30 September 2025** (or face delisting).  \n  - Demonstrate **12-month funding runway** (*via Oakley commitment + additional raises*).  \n- **Other Requirements**: Clear all outstanding reports (quarterly, half-year).  \n\n#### **Commercial Milestones**  \n- **Insurance Sector**: Launched digital underwriting with **Unisure (UK)**; **Bearer/HIQOR** live in US (16 partners).  \n- **AF-Scan**: FDA/EMA-approved atrial fibrillation tool launching H2 2025.  \n- **MENA/US Expansion**: Partnerships with Pharmak (UAE), Bearn LLC, and Kalibra (Singapore).  \n\n#### **Material Risks**  \n- **ASX Delisting Risk**: If FY2024 report not lodged by **30 September 2025**.  \n- **Funding Uncertainty**: USD $6M target not yet secured; KOR facility delayed indefinitely.  \n\n---  \n**Format**: Strictly concise; excludes operational minutiae, director details, and legal boilerplate. Focuses on liquidity, capital structure, and valuation-impacting items.",
  "usage": {
    "prompt_tokens": 18944,
    "completion_tokens": 549,
    "total_tokens": 19493,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T08:42:18.698259"
}